{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:05:46Z","timestamp":1761919546463,"version":"3.30.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1126,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"abstract":"\n \n \n Recent studies have shown that a single-nucleotide polymorphism upstream of the interleukin-28B (<\/jats:bold>\n \n IL28B\n <\/jats:bold>\n ) gene plays a major role in predicting therapeutic response in hepatitis C virus (HCV)-infected patients treated with pegylated interferon (PEG-IFN)\/ribavirin. We sought to investigate the mechanism of the<\/jats:bold>\n \n IL28B\n <\/jats:bold>\n polymorphism, specifically as it relates to early HCV viral kinetics, IFN pharmacokinetics, IFN pharmacodynamics, and gene expression profiles. Two prospective cohorts (human immunodeficiency virus [HIV]\/HCV-coinfected and HCV-monoinfected) completing treatment with IFN\/ribavirin were enrolled. Patients were genotyped at the polymorphic site rs12979860. In the HIV\/HCV cohort, frequent serum sampling was completed for HCV RNA and IFN levels. DNA microarray of peripheral blood mononuclear cells and individual expression of IFN-stimulated genes (ISGs) were quantified on IFN therapy. The<\/jats:bold>\n \n IL28B\n <\/jats:bold>\n -favorable (CC) genotype was associated with improved therapeutic response compared with unfavorable (CT or TT) genotypes. Patients with a favorable genotype had greater first- and second-phase viral kinetics (<\/jats:bold>\n \n P\n <\/jats:bold>\n = 0.004 and<\/jats:bold>\n \n P\n <\/jats:bold>\n = 0.036, respectively), IFN maximum antiviral efficiency (<\/jats:bold>\n \n P\n <\/jats:bold>\n = 0.007) and infected cell death loss (<\/jats:bold>\n \n P\n <\/jats:bold>\n = 0.009) compared with unfavorable genotypes. Functional annotation analysis of DNA microarray data was consistent with depressed innate immune function, particularly of natural killer cells, from patients with unfavorable genotypes (<\/jats:bold>\n \n P\n <\/jats:bold>\n <0.004). Induction of innate immunity genes was also lower in unfavorable genotypes. ISG expression at baseline and induction with IFN was independent of<\/jats:bold>\n \n IL28B\n <\/jats:bold>\n genotype.<\/jats:bold>\n \n Conclusion:\n <\/jats:bold>\n Carriers of the<\/jats:bold>\n \n IL28B\n <\/jats:bold>\n -favorable genotype were more likely to have superior innate immune response to IFN therapy compared with unfavorable genotypes, suggesting that the unfavorable genotype has aberrant baseline induction of innate immune response pathways resulting in impaired virologic response.<\/jats:bold>\n \n IL28B\n <\/jats:bold>\n genotype is associated with more rapid viral kinetics and improved treatment response outcomes independent of ISG expression. (HEPATOLOGY 2012)<\/jats:bold>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/hep.25647","type":"journal-article","created":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T11:40:27Z","timestamp":1329133227000},"page":"444-454","update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":55,"title":["Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B -unfavorable genotype patients: Impaired viral kinetics and therapeutic response"],"prefix":"10.1097","volume":"56","author":[{"given":"Susanna","family":"Naggie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Osinusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonios","family":"Katsounas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Lempicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander J.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Muir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"McHutchison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg F.","family":"Schlaak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Trippler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavana","family":"Shivakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Masur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Polis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyam","family":"Kottilil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-7-20241201","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection.","volume":"345","author":"Lauer","year":"2001","journal-title":"N Engl J Med"},{"key":"R3-7-20241201","doi-asserted-by":"crossref","first-page":"10731089","DOI":"10.1097\/QAD.0b013e3281084e4d","article-title":"Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCVHIV International Panel.","volume":"21","author":"Soriano","year":"2007","journal-title":"AIDS"},{"key":"R4-7-20241201","first-page":"128133","article-title":"Incidence and predictors of severe liver fibrosis in HIVinfected patients with chronic hepatitis C: a European collaborative study.","volume":"38","author":"MartinCarbonero","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R5-7-20241201","doi-asserted-by":"crossref","first-page":"399401","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance.","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"R6-7-20241201","doi-asserted-by":"crossref","first-page":"11001104","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferonalfa and ribavirin therapy.","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"R7-7-20241201","doi-asserted-by":"crossref","first-page":"11051109","DOI":"10.1038\/ng.449","article-title":"Genomewide association of IL28B with response to pegylated interferonalfa and ribavirin therapy for chronic hepatitis C.","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"R8-7-20241201","doi-asserted-by":"crossref","first-page":"F23F29","DOI":"10.1097\/QAD.0b013e3283391d6d","article-title":"Association of a single nucleotide polymorphism near the interleukin28B gene with response to hepatitis C therapy in HIVhepatitis C viruscoinfected patients.","volume":"24","author":"Rallon","year":"2010","journal-title":"AIDS"},{"key":"R9-7-20241201","doi-asserted-by":"crossref","first-page":"18881896","DOI":"10.1002\/hep.23912","article-title":"IL28B genotype is associated with differential expression of intrahepatic interferonstimulated genes in patients with chronic hepatitis C.","volume":"52","author":"Urban","year":"2010","journal-title":"HEPATOLOGY"},{"key":"R10-7-20241201","doi-asserted-by":"crossref","first-page":"499509","DOI":"10.1053\/j.gastro.2010.04.049","article-title":"Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.","volume":"139","author":"Honda","year":"2010","journal-title":"Gastroenterology"},{"key":"R11-7-20241201","doi-asserted-by":"crossref","first-page":"10211031","DOI":"10.1053\/j.gastro.2010.11.039","article-title":"Interferoninduced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.","volume":"140","author":"Dill","year":"2011","journal-title":"Gastroenterology"},{"key":"R12-7-20241201","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/hep.24623","article-title":"Association of gene expression involving innate immunity and genetic variation in IL28B with antiviral response.","volume":"55","author":"Asahina","year":"2012","journal-title":"HEPATOLOGY"},{"key":"R13-7-20241201","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1002\/hep.23055","article-title":"Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells.","volume":"50","author":"Kottilil","year":"2009","journal-title":"HEPATOLOGY"},{"key":"R14-7-20241201","doi-asserted-by":"crossref","first-page":"11721177","DOI":"10.1086\/501365","article-title":"Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of antiHCV therapy among HIVcoinfected persons.","volume":"193","author":"Lempicki","year":"2006","journal-title":"J Infect Dis"},{"key":"R15-7-20241201","doi-asserted-by":"crossref","first-page":"24392450","DOI":"10.1097\/QAD.0b013e32832ff1c0","article-title":"Therapeutic response to pegIFNalfa2b and ribavirin in HIVHCV coinfected AfricanAmerican and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.","volume":"23","author":"Rozenberg","year":"2009","journal-title":"AIDS"},{"key":"R16-7-20241201","doi-asserted-by":"crossref","first-page":"321332","DOI":"10.1517\/17425250902787616","article-title":"Modeling hepatitis C virus kinetics under therapy using pharmacokinetic and pharmacodynamic information.","volume":"5","author":"Shudo","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R17-7-20241201","first-page":"1621","article-title":"Triphasic decline of hepatitis C virus RNA during antiviral therapy.","volume":"46","author":"Dahari","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R18-7-20241201","doi-asserted-by":"crossref","first-page":"13511358","DOI":"10.1053\/jhep.2003.50218","article-title":"Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.","volume":"37","author":"Herrmann","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R19-7-20241201","doi-asserted-by":"crossref","first-page":"922924","DOI":"10.1038\/nature03153","article-title":"Modeling how ribavirin improves interferon response rates in hepatitis C virus infection.","volume":"432","author":"Dixit","year":"2004","journal-title":"Nature"},{"key":"R20-7-20241201","first-page":"9599","article-title":"Pharmacodynamics of PEGIFN alpha2a and HCV response as a function of IL28B polymorphism in HIVHCV coinfected patients.","volume":"56","author":"Affonso de Araujo","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R21-7-20241201","doi-asserted-by":"crossref","first-page":"980988","DOI":"10.1016\/j.jhep.2011.01.050","article-title":"IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.","volume":"55","author":"Bochud","year":"2011","journal-title":"J Hepatol"},{"key":"R22-7-20241201","doi-asserted-by":"crossref","first-page":"10251033","DOI":"10.1097\/QAD.0b013e3283471cae","article-title":"IL28B gene polymorphisms and viral kinetics in HIVhepatitis C viruscoinfected patients treated with pegylated interferon and ribavirin.","volume":"25","author":"Rallon","year":"2011","journal-title":"AIDS"},{"key":"R23-7-20241201","first-page":"15591569","article-title":"Natural killer inhibitory receptor expression associated with treatment failure and interleukin28B genotype in patients with chronic hepatitis C.","volume":"54","author":"GoldenMason","year":"2011","journal-title":"HEPATOLOGY"},{"key":"R24-7-20241201","doi-asserted-by":"crossref","first-page":"323335","DOI":"10.1002\/jcp.20137","article-title":"Alfainterferon and its effects on signal transduction pathways.","volume":"202","author":"Caraglia","year":"2005","journal-title":"J Cell Physiol"},{"key":"R25-7-20241201","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.clim.2009.12.005","article-title":"Innate immunity and chronic immune activation in HCVHIV1 coinfection.","volume":"135","author":"Gonzalez","year":"2010","journal-title":"Clin Immunol"},{"key":"R26-7-20241201","doi-asserted-by":"crossref","first-page":"798801","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"R28-7-20241201","doi-asserted-by":"crossref","first-page":"961972","DOI":"10.1002\/hep.21167","article-title":"Genomic response to interferon in chimpanzees: implications of rapid downregulation for hepatitis C kinetics.","volume":"43","author":"Lanford","year":"2006","journal-title":"HEPATOLOGY"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.25647","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201208000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T14:04:56Z","timestamp":1733061896000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201208000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.25647","relation":{},"ISSN":["0270-9139"],"issn-type":[{"type":"print","value":"0270-9139"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}